Insulet Corporation (PODD)
NASDAQ: PODD · Real-Time Price · USD
182.87
-5.44 (-2.89%)
At close: Apr 28, 2026, 4:00 PM EDT
183.29
+0.42 (0.23%)
After-hours: Apr 28, 2026, 7:04 PM EDT
Insulet Revenue
In the year 2025, Insulet had annual revenue of $2.71B with 30.73% growth. Insulet had revenue of $783.80M in the quarter ending December 31, 2025, with 31.18% growth.
Revenue (ttm)
$2.71B
Revenue Growth
+30.73%
P/S Ratio
4.68
Revenue / Employee
$501,500
Employees
5,400
Market Cap
12.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.71B | 636.50M | 30.73% |
| Dec 31, 2024 | 2.07B | 374.50M | 22.07% |
| Dec 31, 2023 | 1.70B | 391.80M | 30.02% |
| Dec 31, 2022 | 1.31B | 206.50M | 18.79% |
| Dec 31, 2021 | 1.10B | 194.40M | 21.49% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Koninklijke Philips | 20.94B |
| Zimmer Biomet Holdings | 8.23B |
| Smith & Nephew | 6.16B |
| STERIS | 5.83B |
| DexCom | 4.66B |
| Globus Medical | 2.94B |
| Bio-Rad Laboratories | 2.58B |
| Bio-Rad Laboratories | 2.58B |
PODD News
- 12 hours ago - Insulet to Participate in BofA Securities 2026 Health Care Conference - Business Wire
- 27 days ago - Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026 - Business Wire
- 4 weeks ago - Insulet Appoints Mike Panos as Chief Commercial Officer - Business Wire
- 4 weeks ago - PODD Investors Have Opportunity to Join Insulet Corporation Fraud Investigation with the Schall Law Firm - Business Wire
- 6 weeks ago - Insulet recalls some insulin devices in US over leakage risk - Reuters
- 6 weeks ago - Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S. - Business Wire
- 6 weeks ago - Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes - Business Wire
- 7 weeks ago - Insulet to Present EVOLUTION 2 Results on Omnipod® Fully Closed-Loop System for Adults with Type 2 Diabetes at International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) - Business Wire